Copyright © 1998 by the European Society of Cardiology.
Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women
The Scottish Heart Health Study
a Cardiovascular Epidemiology Unit, University of Dundee, Dundee, Scotland
b Department of Applied Statistics, University of Reading, Reading
c University Department of Medicine, Glasgow Royal Infirmary, Glasgow, Scotland, U.K.
accepted May 16, 1997
Aims Fibrinogen was measured in 5095 men and 4860 men aged 40–59 in a random population sample from 25 districts of Scotland recruited during 1984–87: the Scottish Heart Health Study. Fibrinogen was then related to the chance of fatal and non-fatal coronary events and death from any cause during a subsequent follow-up period of around 8 years.
Methods and results Fibrinogen was measured by the Clauss assay. The effect of fibrinogen on coronary heart disease and death was assessed through age-adjusted means and Cox proportional hazards regression models, accounting for age, cotinine (a measure of tobacco smoke inhalation) and 11 other major coronary risk factors. Fibrinogen was found to be an important risk factor for coronary heart disease in men and women, with and without pre-existing coronary heart disease. There appears to be a threshold effect, with those in the highest fifth of the distribution having a much increased risk. Estimated age- adjusted hazard ratios by sex and pre-existing coronary heart disease group for the highest to lowest fifth of fibrinogen range between 1·93 and 4·86. Fibrinogen is also important as a risk factor for coronary death and all-causes mortality, with a similar threshold effect. Comparing the two extreme fifths, the hazard ratios for coronary death are 3·01 and 3·42, and for all-cause mortality are 2·59 and 2·20, for men and women respectively. Adjustment for cotinine reduces the hazard ratios, but further adjustment for the other 11 risk factors has little effect for coronary heart disease events. After full adjustment there is a remaining significant (P<0·05) hazard ratio for coronary death and death from any cause and for a coronary heart disease event for those free of coronary heart disease at baseline, amongst men, comparing the highest to the lowest fifth.
Conclusion Fibrinogen is a strong predictor of coronary heart disease, fatal or non-fatal, new or recurrent, and of death from an unspecified cause, for both men and women. Its effect is only partially attributable to other coronary risk factors, the most important of which is smoking.
Key Words: Fibrinogen • coronary heart disease • all-causes mortality
f1 Correspondence: Professor H. Tunstall-Pedoe, Cardiovascular Epidemiology Unit, Ninewells Hospital, Dundee DD1 9SY, Scotland, U.K.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Iwaki, M. J. Sandoval-Cooper, M. Brechmann, V. A. Ploplis, and F. J. Castellino A fibrinogen deficiency accelerates the initiation of LDL cholesterol-driven atherosclerosis via thrombin generation and platelet activation in genetically predisposed mice Blood, May 15, 2006; 107(10): 3883 - 3891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ziakas, S. Gavrilidis, G. Giannoglou, E. Souliou, K. Gemitzis, D. Kalampalika, M. A. Vayona, I. Pidonia, G. Parharidis, and G. Louridas In-Hospital and Long-Term Prognostic Value of Fibrinogen, CRP, and IL-6 Levels in Patients with Acute Myocardial Infarction Treated with Thrombolysis Angiology, May 1, 2006; 57(3): 283 - 293. [Abstract] [PDF]
|
|
|
|
 |
|
 Fibrinogen Studies Collaboration* Plasma Fibrinogen Level and the Risk of Major Cardiovascular Diseases and Nonvascular Mortality: An Individual Participant Meta-analysis JAMA, October 12, 2005; 294(14): 1799 - 1809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Nasir, E. Guallar, A. Navas-Acien, M. H. Criqui, and J. A.C. Lima Relationship of Monocyte Count and Peripheral Arterial Disease: Results From the National Health and Nutrition Examination Survey 1999-2002 Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1966 - 1971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Soria, L. Almasy, J. C. Souto, A. Buil, M. Lathrop, J. Blangero, and J. Fontcuberta A Genome Search for Genetic Determinants That Influence Plasma Fibrinogen Levels Arterioscler. Thromb. Vasc. Biol., June 1, 2005; 25(6): 1287 - 1292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Kerlin, B. C. Cooley, B. H. Isermann, I. Hernandez, R. Sood, M. Zogg, S. B. Hendrickson, M. W. Mosesson, S. Lord, and H. Weiler Cause-effect relation between hyperfibrinogenemia and vascular disease Blood, March 1, 2004; 103(5): 1728 - 1734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kamath and G.Y.H. Lip Fibrinogen: biochemistry, epidemiology and determinants QJM, October 1, 2003; 96(10): 711 - 729. [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Klein, S. J. Hunter, A. J. Jenkins, D. Zheng, A. J. Semler, J. Clore, W. T. Garvey, and The DCCT/EDIC Study Group Fibrinogen Is a Marker for Nephropathy and Peripheral Vascular Disease in Type 1 Diabetes: Studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort Diabetes Care, May 1, 2003; 26(5): 1439 - 1448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F. De Leon, G. D. Thurston, and K. Ito Contribution of Respiratory Disease to Nonrespiratory Mortality Associations with Air Pollution Am. J. Respir. Crit. Care Med., April 15, 2003; 167(8): 1117 - 1123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Kittel, F. Leynen, M. Stam, M. Dramaix, P. de Smet, R. Mak, G. De Backer, and M. Kornitzer Job conditions and fibrinogen in 14226 Belgian workers. The Belstress study Eur. Heart J., December 1, 2002; 23(23): 1841 - 1848. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. W. Muir Inflammation, Blood Pressure, and Stroke: An Opportunity to Target Primary Prevention? Stroke, December 1, 2002; 33(12): 2732 - 2733. [Full Text] [PDF]
|
|
|
|
|
|
V. Stangl, G. Baumann, and K. Stangl Coronary atherogenic risk factors in women Eur. Heart J., November 2, 2002; 23(22): 1738 - 1752. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Koenig and M. B. Pepys C-Reactive Protein Risk Prediction: Low Specificity, High Sensitivity Ann Intern Med, April 2, 2002; 136(7): 550 - 552. [Full Text] [PDF]
|
|
|
|
|
|
V. Salomaa, V. Rasi, S. Kulathinal, E. Vahtera, M. Jauhiainen, C. Ehnholm, and J. Pekkanen Hemostatic Factors as Predictors of Coronary Events and Total Mortality: The FINRISK '92 Hemostasis Study Arterioscler. Thromb. Vasc. Biol., February 1, 2002; 22(2): 353 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Andersson, G. Johannsson, G. Holm, B.-A. Bengtsson, A. Sashegyi, I. Pavo, T. Mason, and P. W. Anderson Raloxifene Does Not Affect Insulin Sensitivity or Glycemic Control in Postmenopausal Women with Type 2 Diabetes Mellitus: A Randomized Clinical Trial J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 122 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yano, J. S. Grove, R. Chen, B. L. Rodriguez, J. D. Curb, and R. P. Tracy Plasma Fibrinogen as a Predictor of Total and Cause-Specific Mortality in Elderly Japanese-American Men Arterioscler. Thromb. Vasc. Biol., June 1, 2001; 21(6): 1065 - 1070. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Lind, B. Hedblad, L. Stavenow, L. Janzon, K. F. Eriksson, and F. Lindgarde Influence of Plasma Fibrinogen Levels on the Incidence of Myocardial Infarction and Death Is Modified by Other Inflammation-Sensitive Proteins : A Long-Term Cohort Study Arterioscler. Thromb. Vasc. Biol., March 1, 2001; 21(3): 452 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sato, M. Nakamura, M. Iida, Y. Naito, A. Kitamura, T. Okamura, Y. Nakagawa, H. Imano, M. Kiyama, H. Iso, et al. Plasma Fibrinogen and Coronary Heart Disease in Urban Japanese Am. J. Epidemiol., September 1, 2000; 152(5): 420 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. F. Bielak, G. G. Klee, P. F. Sheedy II, S. T. Turner, R. S. Schwartz, and P. A. Peyser Association of Fibrinogen With Quantity of Coronary Artery Calcification Measured by Electron Beam Computed Tomography Arterioscler. Thromb. Vasc. Biol., September 1, 2000; 20(9): 2167 - 2171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Fischer, D. E Gutstein, Z. A Fayad, and V. Fuster Predicting plaque rupture: enhancing diagnosis and clinical decision-making in coronary artery disease Vascular Medicine, August 1, 2000; 5(3): 163 - 172. [Abstract] [PDF]
|
|
|
|
|
|
G. Maresca, A. Di Blasio, R. Marchioli, and G. Di Minno Measuring Plasma Fibrinogen to Predict Stroke and Myocardial Infarction : An Update Arterioscler. Thromb. Vasc. Biol., June 1, 1999; 19(6): 1368 - 1377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Gutstein and V. Fuster Pathophysiology and clinical significance of atherosclerotic plaque rupture Cardiovasc Res, February 1, 1999; 41(2): 323 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Eriksson, N. Egberg, S. Wamala, K. Orth-Gomer, M. A. Mittleman, and K. Schenck-Gustafsson Relationship Between Plasma Fibrinogen and Coronary Heart Disease in Women Arterioscler. Thromb. Vasc. Biol., January 1, 1999; 19(1): 67 - 72. [Abstract] [Full Text] [PDF]
|
|